AIMS: Increasing evidence suggests a potential role of circulating miRNAs as clinical biomarkers, and loss of miRNA-126 has been proposed as a predictor of type 2 diabetes onset. However, a systematic analysis of circulating miRNAs in type 1 diabetic patients with micro-/macrovascular complications has not yet been performed. METHODS: A cross-sectional nested case-control study from the EURODIAB Prospective Complications Study of 455 type 1 diabetic patients was performed. Case subjects (n = 312) were defined as those with one or more complications of diabetes; control subjects (n = 143) were those with no evidence of any complication. A differential miRNA expression profiling was performed in pooled serum samples from cases and controls. Furthermore, miR-126 levels were quantified by qPCR in all individual samples and associations with diabetic complications investigated. RESULTS: Twenty-five miRNAs differed in pooled samples from cases and controls. miR-126 levels were significantly lower in case than in control subjects, even after adjustment for age and sex. In logistic regression analyses, miR-126 was negatively associated with all complications (OR = 0.85, 95 % CI 0.75-0.96) as well as with each micro-/macrovascular complication examined separately. This was likely dependent of diabetes as associations were no longer significant after adjustment for both hyperglycemia and diabetes duration. However, a significant 25 % risk reduction, independent of age, sex, A1C, and diabetes duration, was still observed for proliferative retinopathy (OR = 0.75, 95 % CI 0.59-0.95). CONCLUSIONS: In this large cohort of type 1 diabetic subjects, we found that miR-126 levels are associated with vascular complications of diabetes, particularly with proliferative retinopathy.

MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study

BARUTTA, FEDERICA
First
;
BRUNO, Graziella;MATULLO, Giuseppe;GRIMALDI, SERENA;GRUDEN, Gabriella
Last
2017-01-01

Abstract

AIMS: Increasing evidence suggests a potential role of circulating miRNAs as clinical biomarkers, and loss of miRNA-126 has been proposed as a predictor of type 2 diabetes onset. However, a systematic analysis of circulating miRNAs in type 1 diabetic patients with micro-/macrovascular complications has not yet been performed. METHODS: A cross-sectional nested case-control study from the EURODIAB Prospective Complications Study of 455 type 1 diabetic patients was performed. Case subjects (n = 312) were defined as those with one or more complications of diabetes; control subjects (n = 143) were those with no evidence of any complication. A differential miRNA expression profiling was performed in pooled serum samples from cases and controls. Furthermore, miR-126 levels were quantified by qPCR in all individual samples and associations with diabetic complications investigated. RESULTS: Twenty-five miRNAs differed in pooled samples from cases and controls. miR-126 levels were significantly lower in case than in control subjects, even after adjustment for age and sex. In logistic regression analyses, miR-126 was negatively associated with all complications (OR = 0.85, 95 % CI 0.75-0.96) as well as with each micro-/macrovascular complication examined separately. This was likely dependent of diabetes as associations were no longer significant after adjustment for both hyperglycemia and diabetes duration. However, a significant 25 % risk reduction, independent of age, sex, A1C, and diabetes duration, was still observed for proliferative retinopathy (OR = 0.75, 95 % CI 0.59-0.95). CONCLUSIONS: In this large cohort of type 1 diabetic subjects, we found that miR-126 levels are associated with vascular complications of diabetes, particularly with proliferative retinopathy.
2017
54
133
139
link.springer.de/link/service/journals/00592/index.htm
Complications; MicroRNAs; Retinopathy; Type 1 diabetes; Internal Medicine; Endocrinology, Diabetes and Metabolism; Endocrinology
Barutta, Federica; Bruno, Graziella; Matullo, Giuseppe; Chaturvedi, Nish; Grimaldi, Serena; Schalkwijk, Casper; Stehouwer, Coen D.; Fuller, John H.; Gruden, Gabriella
File in questo prodotto:
File Dimensione Formato  
mir126 finale Acta.docx

Accesso riservato

Descrizione: pre-print
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 47.63 kB
Formato Microsoft Word XML
47.63 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
2017_Barutta.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 392.61 kB
Formato Adobe PDF
392.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
ACDI-D-16-00222_R1 (1).pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 532.21 kB
Formato Adobe PDF
532.21 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1620304
Citazioni
  • ???jsp.display-item.citation.pmc??? 42
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 73
social impact